Gastroenterology. 2021 Aug 3;S0016-5085(21)03337-0.doi: 10.1053/j.gastro.2021.07.042. Online ahead of print.

Gerhard Rogler ¹, Abha Singh ², Arthur Kavanaugh ², David T Rubin ³

Author information

• ¹Department of Gastroenterology and Hepatology, Department of Medicine, Zurich University Hospital, Zurich, Switzerland.
• ²University of California, San Diego, La Jolla, California.
• ³University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, Illinois. Electronic address: drubin@uchicago.edu.

Abstract

Inflammatory bowel diseases (IBDs) are systemic diseases that manifest not only in the gut and gastrointestinal tract, but also in the extraintestinal organs in many patients. The quality of life for patients with IBD can be substantially affected by these extraintestinal manifestations (EIMs). It is important to have knowledge of the prevalence, pathophysiology, and clinical presentation of EIMs in order to adapt therapeutic options to cover all aspects of IBD. EIMs can occur in up to 24% of patients with IBD before the onset of intestinal symptoms, and need to be recognized to initiate appropriate diagnostic procedures. EIMs most frequently affect joints, skin, or eyes, but can also affect other organs, such as the liver, lung, and pancreas. It is a frequent misconception that a successful therapy of the intestinal inflammation will be sufficient to treat EIMs satisfactorily in most patients with IBD. In general, peripheral arthritis, oral aphthous ulcers, episcleritis, or erythema nodosum can be associated with active intestinal inflammation and can improve on standard treatment of the intestinal inflammation. However, anterior uveitis, ankylosing spondylitis, and primary sclerosing cholangitis usually occur independent of disease flares. This review provides a comprehensive overview of epidemiology, pathophysiology, clinical presentation, and treatment of EIMs in IBD.